X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA FULFORD INDIA PLETHICO PHARMA/
FULFORD INDIA
 
P/E (TTM) x -1.1 398.8 - View Chart
P/BV x 0.0 6.2 0.3% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PLETHICO PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
FULFORD INDIA
Mar-14
PLETHICO PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs395942 41.9%   
Low Rs31450 7.0%   
Sales per share (Unadj.) Rs604.4691.4 87.4%  
Earnings per share (Unadj.) Rs32.511.5 283.4%  
Cash flow per share (Unadj.) Rs51.315.4 334.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs473.6380.0 124.6%  
Shares outstanding (eoy) m34.083.90 873.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.41.0 35.0%   
Avg P/E ratio x6.660.7 10.8%  
P/CF ratio (eoy) x4.245.3 9.2%  
Price / Book Value ratio x0.51.8 24.6%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m7,2622,714 267.6%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m1,596505 316.0%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m20,5982,696 763.9%  
Other income Rs m386125 308.1%   
Total revenues Rs m20,9842,822 743.7%   
Gross profit Rs m2,818-46 -6,072.5%  
Depreciation Rs m64215 4,225.7%   
Interest Rs m1,59310 16,770.5%   
Profit before tax Rs m96954 1,783.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-13810 -1,441.5%   
Profit after tax Rs m1,10745 2,476.2%  
Gross profit margin %13.7-1.7 -794.9%  
Effective tax rate %-14.317.7 -80.8%   
Net profit margin %5.41.7 324.2%  
BALANCE SHEET DATA
Current assets Rs m18,8771,738 1,085.9%   
Current liabilities Rs m11,896545 2,184.0%   
Net working cap to sales %33.944.3 76.6%  
Current ratio x1.63.2 49.7%  
Inventory Days Days3648 74.1%  
Debtors Days Days1984 4,595.6%  
Net fixed assets Rs m9,86112 82,861.3%   
Share capital Rs m34139 873.6%   
"Free" reserves Rs m12,3311,443 854.5%   
Net worth Rs m16,1391,482 1,089.0%   
Long term debt Rs m4,7060-   
Total assets Rs m33,1462,077 1,596.1%  
Interest coverage x1.66.7 23.9%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.61.3 47.9%   
Return on assets %8.12.6 312.1%  
Return on equity %6.93.0 227.4%  
Return on capital %12.34.3 285.5%  
Exports to sales %21.40-   
Imports to sales %15.224.5 62.3%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,136659 475.7%   
Fx inflow Rs m4,40217 25,595.3%   
Fx outflow Rs m3,184673 473.0%   
Net fx Rs m1,219-656 -185.8%   
CASH FLOW
From Operations Rs m2,43790 2,708.2%  
From Investments Rs m-6,265105 -5,989.2%  
From Financial Activity Rs m2,490-14 -17,660.3%  
Net Cashflow Rs m-1,337181 -740.8%  

Share Holding

Indian Promoters % 82.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.3 3.8 113.2%  
FIIs % 5.5 0.1 5,500.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 21.2 35.4%  
Shareholders   10,665 4,783 223.0%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS